Literature DB >> 18274731

Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study.

Tomohiro Kobayashi1, Etsuko Hayashi, Midori Shimamura, Mine Kinoshita, Niall P Murphy.   

Abstract

RATIONALE: Marble burying and forced swimming behavior are widely used and sensitive tests for identifying clinically effective antidepressant drugs, although the underlying neurobiology of these behaviors is not fully elucidated.
OBJECTIVES: The objective of this study was to determine the relationship between the behavioral effects of antidepressant drugs and their ability to modulate extracellular neurotransmitter levels in the prefrontal cortex.
MATERIALS AND METHODS: The effects of fluoxetine, fluvoxamine, citalopram, imipramine, and desipramine (0 to 60 mg/kg by oral gavage, except fluoxetine at 0 to 40 mg/kg) were studied independently in CD-1 mice in the marble-burying task, forced swim task and on extracellular concentrations of serotonin, norepinephrine, and dopamine in the prefrontal cortex by freely moving microdialysis.
RESULTS: Fluvoxamine, fluoxetine, and citalopram all suppressed marble-burying behavior, but produced no change in immobility time in the forced swim test. In contrast, imipramine and desipramine suppressed both marble-burying behavior and increased swimming time in the forced swim test, although desipramine mildly suppressed locomotor activity at the maximal dose. Fluvoxamine, fluoxetine, and citalopram all increased extracellular levels of cortical serotonin. Desipramine and imipramine increased extracellular dopamine levels. Fluoxetine, desipramine, and imipramine increased extracellular norepinephrine levels. Correlational analysis revealed a positive correlation between efficacy of drugs in the forced swim test and cortical extracellular dopamine levels, whereas a positive correlation was found between efficacy in the marble-burying test and extracellular serotonin levels.
CONCLUSIONS: Although marble burying and forced swimming behavior have strong predictive validity in tests of antidepressant action, each assay appears to be underpinned by entirely different neurochemical systems.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18274731     DOI: 10.1007/s00213-008-1070-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  74 in total

Review 1.  A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression.

Authors:  J C Nelson
Journal:  Biol Psychiatry       Date:  1999-11-01       Impact factor: 13.382

Review 2.  What should animal models of depression model?

Authors:  Alan Frazer; David A Morilak
Journal:  Neurosci Biobehav Rev       Date:  2005       Impact factor: 8.989

3.  Effect of YM992, a novel antidepressant with selective serotonin re-uptake inhibitory and 5-HT 2A receptor antagonistic activity, on a marble-burying behavior test as an obsessive-compulsive disorder model.

Authors:  Hiromi Takeuchi; Shin-ichi Yatsugi; Tokio Yamaguchi
Journal:  Jpn J Pharmacol       Date:  2002-10

4.  The neurobiology of obsessive-compulsive disorder.

Authors:  J L Rapoport
Journal:  JAMA       Date:  1988-11-18       Impact factor: 56.272

5.  Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.

Authors:  Mauricette Brocco; Anne Dekeyne; Mariusz Papp; Mark J Millan
Journal:  Behav Pharmacol       Date:  2006-11       Impact factor: 2.293

6.  S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine.

Authors:  M J Millan; A Dekeyne; M Papp; C D La Rochelle; C MacSweeny; J L Peglion; M Brocco
Journal:  J Pharmacol Exp Ther       Date:  2001-08       Impact factor: 4.030

7.  Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.

Authors:  E H Wong; M S Sonders; S G Amara; P M Tinholt; M F Piercey; W P Hoffmann; D K Hyslop; S Franklin; R D Porsolt; A Bonsignori; N Carfagna; R A McArthur
Journal:  Biol Psychiatry       Date:  2000-05-01       Impact factor: 13.382

8.  An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients.

Authors:  G Chouinard; L Annable; J Bradwejn
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Effects of antidepressants in the rat forced swimming test.

Authors:  Y Kitada; T Miyauchi; A Satoh; S Satoh
Journal:  Eur J Pharmacol       Date:  1981-06-19       Impact factor: 4.432

10.  5-HT1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marble-burying behavior in mice.

Authors:  Y Ichimaru; T Egawa; A Sawa
Journal:  Jpn J Pharmacol       Date:  1995-05
View more
  19 in total

1.  Rat strain differences in restraint stress-induced brain cytokines.

Authors:  V M Porterfield; Z R Zimomra; E A Caldwell; R M Camp; K M Gabella; J D Johnson
Journal:  Neuroscience       Date:  2011-05-18       Impact factor: 3.590

2.  Deficient serotonin neurotransmission and depression-like serotonin biomarker alterations in tryptophan hydroxylase 2 (Tph2) loss-of-function mice.

Authors:  J P R Jacobsen; W B Siesser; B D Sachs; S Peterson; M J Cools; V Setola; J H A Folgering; G Flik; M G Caron
Journal:  Mol Psychiatry       Date:  2011-05-03       Impact factor: 15.992

Review 3.  Rodent models of treatment-resistant depression.

Authors:  Barbara J Caldarone; Venetia Zachariou; Sarah L King
Journal:  Eur J Pharmacol       Date:  2014-11-21       Impact factor: 4.432

4.  Functional interactions between 5-HT2A and presynaptic 5-HT1A receptor-based responses in mice genetically deficient in the serotonin 5-HT transporter (SERT).

Authors:  Meredith A Fox; Alison R Stein; Helen T French; Dennis L Murphy
Journal:  Br J Pharmacol       Date:  2010-01-27       Impact factor: 8.739

5.  The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.

Authors:  Jacob P R Jacobsen; Per Plenge; Benjamin D Sachs; Alan L Pehrson; Manuel Cajina; Yunzhi Du; Wendy Roberts; Meghan L Rudder; Prachiti Dalvi; Taylor J Robinson; Sharon P O'Neill; King S Khoo; Connie Sanchez Morillo; Xiaodong Zhang; Marc G Caron
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

6.  The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting.

Authors:  Francesco Benedetti; Cristina Colombo; Adele Pirovano; Elena Marino; Enrico Smeraldi
Journal:  Psychopharmacology (Berl)       Date:  2008-11-07       Impact factor: 4.530

7.  Mouse plasmacytoma-expressed transcript 1 knock out induced 5-HT disruption results in a lack of cognitive deficits and an anxiety phenotype complicated by hypoactivity and defensiveness.

Authors:  T L Schaefer; C V Vorhees; M T Williams
Journal:  Neuroscience       Date:  2009-09-25       Impact factor: 3.590

8.  Gestational and lactational exposure to atrazine via the drinking water causes specific behavioral deficits and selectively alters monoaminergic systems in C57BL/6 mouse dams, juvenile and adult offspring.

Authors:  Zhoumeng Lin; Celia A Dodd; Shuo Xiao; Saritha Krishna; Xiaoqin Ye; Nikolay M Filipov
Journal:  Toxicol Sci       Date:  2014-06-09       Impact factor: 4.849

Review 9.  Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy.

Authors:  Lynette C Daws
Journal:  Pharmacol Ther       Date:  2008-10-29       Impact factor: 12.310

10.  A Synbiotic Mixture Augmented the Efficacy of Doxepin, Venlafaxine, and Fluvoxamine in a Mouse Model of Depression.

Authors:  Azadeh Mesripour; Andiya Meshkati; Valiollah Hajhashemi
Journal:  Turk J Pharm Sci       Date:  2020-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.